In 2017, Xintela took numerous steps that enabled the company to grow into a prominent player in the field of regenerative medicine, including building its own GMP facility for stem cell production. We also broadened our product options within the cancer project by licensing human antibodies that bind to our integrin markers.
Construction of our GMP facility for stem cell production dominated the first few months of 2018. Work is progressing according to plan. The offices and clean room will soon be finished and ready to be equipped with bio reactors and other critical production equipment. In connection with this, Xintela will move into new offices directly adjacent to the GMP facility. Our GMP lab is designed to produce cells for clinical trials and is prepared for expansion.
Xintela’s decision to build its own GMP facility for stem cell production was a strategically vital step. It gives Xintela a unique and strong position in the field of stem cells and has already attracted a great deal of attention in discussions with potential partners. It is also very satisfying that we already have functioning upscaled methods for producing stem cells from both horses and humans, ensuring that we will have GMP-certified production before the end of the year.
Xintela has also made good progress in its cancer project for treating the severe form of brain cancer known as glioblastoma. We are currently preparing to publish the project findings in order to further spread Xintela’s work within the field. We are also highly active in partnering conferences and have identified several potential partners. It is particularly gratifying that we were able to present, in December, an agreement to license human antibodies that bind to Xintela’s markers integrin α10β1 and integrin α11β1 and which can be used to further develop new products in cancer therapy and diagnostics.
Among other topics, you can read about our exciting partnership with Japanese CellSeed and licensing of antibodies for cancer projects in this newsletter. We also highlight one example of Japan’s dynamic cell therapy market, where a recent bid on one of Europe´s leading cell therapy companies demonstrates the robust economic potential and increased willingness to pay by major players in the field of regenerative medicine.
Sincerely,
Evy Lundgren-Åkerlund
CEO, Xintela AB
